Tissue repair in osteoradionecrosis using pentoxifylline and tocopherol—report of three cases

被引：10
作者：
Bohn J.C. [1 ]
Schussel J.L. [1 ,2 ]
Stramandinoli-Zanicotti R.T. [1 ]
Sassi L.M. [1 ]
机构：
[1] Department of Oral and Maxillofacial Surgery, Erasto Gaertner Hospital, Rua Dr. Ovande do Amaral, 201, Curitiba, 81520-060, PR
[2] Graduate Program in Dentistry, Department of Stomatology, Universidade Federal do Paraná, Curitiba, PR
来源：
Oral and Maxillofacial Surgery | 2016年 / 20卷 / 1期
关键词：
Osteoradionecrosis; Pentoxifylline; Radiotherapy; Tocopherol;
D O I：
10.1007/s10006-015-0522-5
中图分类号：
学科分类号：
摘要：
Purpose: Osteoradionecrosis is a complication of head and neck radiotherapy, with a difficult resolution and no well-established treatment. The disease progression can cause important loss on patient’s quality of life after cancer treatment. The options for treatment are limited and include clinical monitoring, prescription, or surgical procedures. As an alternative for bone necrosis treatment, a combination of drugs, pentoxifylline and tocopherol, can be used. Studies have shown that this combination significantly reduces chronic radiotherapy damage. The article reports successful treatment with this prescription protocol. Methods: We report three cases of patients referred to the Service of Oral and Maxillofacial Surgery at Erasto Gaertner Hospital, in Curitiba, Brazil. They were submitted to radiotherapy for the treatment of malignant head and neck tumors and later developed osteoradionecrosis. They were treated with the combination pentoxifylline and tocopherol. Results: All patients achieved complete remission in less than 1 year, with complete healing of bone exposure and without clinical symptoms. Conclusions: This results show that this combination of drugs is beneficial in cases of bone necrosis induced by radiation, avoiding more aggressive treatments and reducing morbidity. © 2015, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码：97 / 101
页数：4
相关论文
共 31 条
  • [1] Almazrooa S.A., Woo S.B., Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review, J Am Dent Assoc, 140, 7, pp. 864-875, (2009)
  • [2] Marx R.E., Osteoradionecrosis: a new concept of its pathophysiology, J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg, 41, 5, pp. 283-288, (1983)
  • [3] Okunieff P., Augustine E., Hicks J.E., Cornelison T.L., Altemus R.M., Naydich B.G., Ding I., Huser A.K., Abraham E.H., Smith J.J., Coleman N., Gerber L.H., Pentoxifylline in the treatment of radiation-induced fibrosis, J Clin Oncol Off J Am Soc Clin Oncol, 22, 11, pp. 2207-2213, (2004)
  • [4] Delanian S., Lefaix J.L., Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate, Br J Radiol, 75, 893, pp. 467-469, (2002)
  • [5] Balogh J.M., Sutherland S.E., Osteoradionecrosis of the mandible: a review, J Otolaryngol, 18, 5, pp. 245-250, (1989)
  • [6] Delanian S., Lefaix J.L., The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway, Radiother Oncol J Eur Soc Ther Radiol Oncol, 73, 2, pp. 119-131, (2004)
  • [7] Annane D., Depondt J., Aubert P., Villart M., Gehanno P., Gajdos P., Chevret S., Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 study group, J Clin Oncol Off J Am Soc Clin Oncol, 22, 24, pp. 4893-4900, (2004)
  • [8] Balazs C., Kiss E., Immunological aspects of the effect of pentoxifylline (Trental) (a brief review), Acta Microbiol Immunol Hung, 41, 2, pp. 121-126, (1994)
  • [9] Marques L.J., Zheng L., Poulakis N., Guzman J., Costabel U., Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages, Am J Respir Crit Care Med, 159, 2, pp. 508-511, (1999)
  • [10] Berman B., Duncan M.R., Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity, J Invest Dermatol, 92, 4, pp. 605-610, (1989)
1234